Zbigniew Gaciong

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 206 citations · Full text

Molecular Pharmacology, Hypertension, Resistant Hypertension +9

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens et al. · Journal of the American Heart Association · 2016 · 196 citations · Full text

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Prakriti Gaba, Michelle L. O’Donoghue, Jeong‐Gun Park et al. · Circulation · 2023 · 150 citations

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

Brian A. Bergmark, Michelle L. O’Donoghue, Sabina A. Murphy et al. · JAMA Cardiology · 2020 · 124 citations · Full text